Patient Buzz: The Staph-Itch Connection | The Expert Weighs In
HealthCentral recently highlighted new research out of Harvard Medical School on the role of Staphylococcus aureus (S. aureus) in itch. Researchers found S. aureus can trigger itch in mice and human cells through communication with sensory neurons.
For an expert’s take, I reached out to Gil Yosipovitch, MD, professor, Stiefel Chair of Medical Dermatology and director of the Miami Itch Center …
HealthCentral recently highlighted new research out of Harvard Medical School on the role of Staphylococcus aureus (S. aureus) in itch. Researchers found S. aureus can trigger itch in mice and human cells through communication with sensory neurons.
For an expert’s take, I reached out to Gil Yosipovitch, MD, professor, Stiefel Chair of Medical Dermatology and director of the Miami Itch Center … Continue reading "Patient Buzz: The Staph-Itch Connection | The Expert Weighs In"
ABSTRACT
Dyschromia is a concern for many patients, especially persons of color. Postinflammatory hypopigmentation and depigmentation can affect all skin types; however, it is more apparent in those with darker skin. Some members of the dermatology community may not comprehensively understand the mechanisms of these reactions and the extent of the psychosocial effect they have on persons of color … 
Chronic idiopathic urticaria is urticaria for greater than 6 weeks without an identifiable trigger. Cases relapse in 20% of patients for more than 5 years and be difficult to manage; however, omalizumab is a recently approved option for treatment of chronic idiopathic urticaria showing beneficial outcomes.1 Omalizumab is an injectable monoclonal antibody that has been FDA approved not just for chr … 
Atopic dermatitis (AD) is a chronic skin condition characterized by pruritus, inflammation, and acute flare-ups of eczematous lesions over dry skin.1 The wide range of clinical manifestations, the visible nature of the disease, and the intense itching significantly affects patients’ quality of life.2 Up to 80% of children with AD experience sleep disturbances.3 Sixty-seven percent of children … 
During the recent DERM2O22 NP/PA CME conference held July 28-31, 2022, Drs. David Cohen, Brad Glick, and Adam Friedman led a case-based panel discussion on atopic dermatitis (AD) treatment initiation and monitoring. This article provides a summary of their discussion and recommendations.
CASE 1
51-year-old male with a 20-year history of AD. The patient was first seen in September 2015 with BSA … 